These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18786813)

  • 1. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
    Kwon JS; Kim E; Kang DH; Choi JS; Yu KS; Jang IJ; Shin SG;
    Eur Neuropsychopharmacol; 2008 Dec; 18(12):897-907. PubMed ID: 18786813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
    J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
    Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
    J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
    Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
    Chen SF; Shen YC; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):470-4. PubMed ID: 19302829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers.
    Kim E; Kwon JS; Shin YW; Lee JS; Kang WJ; Jo HJ; Lee JM; Yu KS; Kang DH; Cho JY; Jang IJ; Shin SG
    Pharmacogenet Genomics; 2008 Feb; 18(2):91-7. PubMed ID: 18192895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No influence of FAT polymorphisms in response to aripiprazole.
    Pae CU; Chiesa A; Mandelli L; De Ronchi D; Serretti A
    J Hum Genet; 2010 Jan; 55(1):32-6. PubMed ID: 19893579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of aripiprazole in the treatment of first-episode schizophrenia.
    Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
    Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
    Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
    Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
    Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.